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a b s t r a c t
Magnetic resonance imaging is widely used in diagnosing multiple sclerosis as a basic
method for detecting and monitoring the disease.
Introduction: Polish Medical Society of Radiology presents the second version of the recom-
mendations for the routinely conducted MRI in multiple sclerosis, which include new data
and practical remarks for radiographers and radiologists. The recommended protocol aims
to improve the imaging procedure and, most importantly, to standardize conducting MRI
scans in all MRI departments. This is crucial for monitoring the patients with MS, which
directly contributes to essential clinical decisions.
Aim of the guidelines: Multiple sclerosis (MS) is a chronic inﬂammatory demyelinating and
degenerative disease of the central nervous system (CNS) with its etiology still unknown. The
fundamental requirement of the disease is the CNS destruction process disseminated in time
(DIT) and space (DIS). MR imaging detects focal lesions in white and gray matter with high
sensitivityandisthebestwaytoassessbrainatrophyinMSpatients. It isunquestionablythebest
diagnostic tool to follow-up the clinical course of the disease and treatment of MS patients.
However, to achieve a diagnosis based onMRI scans, and follow-upMSpatients according to the
latest standards, anMRI scanhas tomeet certainquality criteria that are thesubject of thiswork.
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E-mail addresses: marek.sasiadek@umed.wroc.pl (M. Sąsiadek), katarzyna_katulska@op.pl (K. Katulska).
https://doi.org/10.1016/j.pjnns.2018.09.010
0028-3843/© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
n e u r o l o g i a i n e u r o ch i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 6 3 8 – 6 4 2 6391. Guidelines for conducting MRI in MS
patients with 1.5 Tesla MRI scanners
1.1. General remarks
Whenperforming anMRI scan ofMS patients, it is necessary to
administer an intravenous paramagnetic contrast agent
(gadolinium) tomake a preliminary diagnosis,monitor disease
progression and treatment response. In view of the high
frequency of contrast-enhanced MRI scans in MS patients,
administration of linear gadolinium-based contrast agents
(GBCAs) to MS patients is not recommended.
For the time being, there is no evidence that gadolinium
deposition in the brain has caused any harm to patients.
However, EMA has recommended restrictions and suspen-
sions for some intravenous linear agents to prevent any risks
that might potentially be associated with gadolinium brain
deposition. Therefore, performing contrast-enhanced MRI
scans is not recommended unless – according to the referring
neurologist – there are absolute indications for administering
an intravenous contrast agent.
In line with the recommendations of medical professionals
and medical literature, we argue that there is no need to
administer a contrast agent (gadolinium) in clinically stable
patients that have been given immunomodulatory treatment
for a long period of time. However, the current regulations of
the Polish National Health Fund drug program impose the
obligation of performing a contrast-enhanced MRI scan in MS
patients every 12 months[3_TD$DIFF] [9].
Procedures performed in patients with Clinically Isolated
Syndrome (CIS) or in patients with suspected MS[4_TD$DIFF] [1–4]:Table 1 – MRI scan protocol of the head.
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nRI scan of the head with the IV contrast agent (Table 1)
 It is recommended to scan the cervical and/or thoracic spinal
cord (according to the neurologist referral/recommendation)
with the IV contrast (Table 2). An MRI examination of the
spinal cord is especially important for diagnosing primary
progressive MS in accordance with the existing diagnostic
criteria (Appendix) In patients with multifocal nervous system damage that
entails the symptomatology associated with the brain and
spinal cord damage, it is possible – depending on the
recommendations of the referring neurologist – to perform
an MRI scan of the head and the chosen part of the spinal
cord at the same time and using oneMRI protocol in order to
shorten the time of diagnostic evaluation (Table 3).
Recommendations for monitoring the clinical course of the
disease based on MR imaging[5_TD$DIFF] [4–8]: MR imaging of the headwith IV contrast to image new active
lesions (Table 1) It is recommended to scan the cervical and/or thoracic spinal
cord (according to the neurologist referral/recommendation)
with the IV contrast agent, especially in primary progressive
MS (Table 2).
1.2. MR brain imaging protocol for patients with multiple
sclerosis
To achieve the same scanning planes, it is recommended to
obtain the true midline plane at follow-up visits.Description
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Table 2 – MRI scan protocol of the spinal cord.
Parameters Description
Electromagnetic ﬁeld Images should be of high quality, with appropriate SNR value and resolution (≤1  1 mm)
Scanned area Scan of the cervical spinal cord
Slice thickness and gaps Sagittal: ≤3 mm, without the gaps (in 2D and 3D acquisition)
Axial: 3 mm, without the gaps
Basic sequences 1. T2-weighted sagittal
2. T1-weighted sagittal
Contrast administration:a T1-weighted sequence within minimum 5,
maximum 10 min after administration
3. T2-weighted, fat saturation (STIR) sagittal
4. T2-weighted axial on the level of lesions visible in SAG sequences
5. T1-weighted sagittal
6. T1-weighted axial
aThe recommended dose of the contrast agent is 0.1 mmol/kg body weight (not linear – see:
General remarks)
Optional sequences 1. T2-weighted coronal on the level of lesions visible in STIR SAG
2. 3D T1-weighted sagittal (for atrophy assessment)
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weighted sagittal 3 mm thick slices should be planned as
thoroughly as possible. The slices should be planned exactly
parallel to the longitudinal ﬁssure of the brain, using
localization slices in transverse and coronal planes. Out of
the ﬁve slices, the third one should pass through the medial
ﬁssure of the brain as precisely as possible.
On the base of the obtained median slice, transverse slices
should be planned parallel to the inferior edge of the rostrum
(anterior commissure, AC) and the splenium of the corpus
callosum(posterior commissure,AP), along theAC-PC line (Fig. 1).
ATTENTION: At follow-up visits, while planning the scan
plane based on the position of corpus callosum, it is necessary
to compare the slice angle of the planned slices to the angle of
the previously obtained slices.
In some scanners it is impossible to save a particular slice,
which is the best for such comparison. In cases like that the
slice should be carefully planned as shown in the ﬁgure
below.Table 3 – Joined MRI scan protocol of the head and the spinal
Parameters
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direction from bottom to top, whereas while scanning in
sagittal planes the direction is from right to left (also while
scanning the cervical spine).2. The gap between the slices should be as small as possible
(suggested 0.3 mm, i.e. 10% of the slice thickness).3. 3D T1-weighted sequence is recommended as the ﬁrst
sequence to avoid MRI motion artifacts over time. This
sequence is crucial for precise volumetric assessment of the
brain.4. Both FLAIR sequences have to be post-contrast sequences
to delay the beginning of T1-weighted CE acquisition
(within 5–10 min after contrast administration) to obtain
better contrast enhancement. The contrast agent does not
affect the quality of FLAIR images, while the time the
patient spends in the scanner is optimized.d.
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Fig. 1 – Reference line positioned parallelly to the corpus callosum.
Table 4 – Multifocal central nervous system damage developed over time according to the 2017 McDonald criteria.
Multifocal CNS damage
disseminated in space (DIS)
CNS damage disseminated in time (DIT)
At least 1 lesion on T2-weighted
scans in two anatomical
locations:
1. Juxtacortical/cortical
2. Periventricular
3. Infratentorial
4. In the spinal cord
New lesions on T2-weighted scans and/or enhancing lesions on follow-up MRI, with
reference to a baseline scan, irrespective of the timing of the baseline MRI or
Simultaneous presence of enhancing and non-enhancing lesions after contrast agent
administration, irrespective of the timing of either the MRI or neurological symptoms
occurrence (also primary scan)
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they should be used with the secondary transverse 3 mm
thick slices reconstruction on the plane planned to the
inferior edge of the corpus callosum.6. If possible, please use the software that automatically plans
the angle and the scannedarea based on the previous scans.
The radiology report should contain the standard termi-
nology for assessing the brain.
Focal lesions assessment:1. Anatomical location (supratentorial: cortical, juxtacortical,
central white matter, periventricular, infratentorial, the
area of corpus callosum, brainstem, spinal cord)2. Size – if many lesions are visible, please include the longest
dimension from-to3. Number of demyelinating lesions – it should be indicated in
the following format: 1, 2, 3–8, ≥94. Character of the lesion, i.e., specify whether the image is
typical for MS demyelination or differential diagnosis is
required, e.g. ischemic focus5. Are the lesions disseminated in space (DIS) and meet the
2017 McDonald criteria (Appendix)6. Comparison to previous scans, i.e., presence of new
lesions and if they meet the dissemination in time
(DIT) criteria, according to the 2017 McDonald criteria
(Appendix)7. Comparison to previous scan with regard to the size of the
demyelinating lesions8. Activity assessment, i.e., number of contrast enhancing
lesions on a current scan and the number of new lesions
with reference to a previous scan – indicated in the
following format: 1, 2, 3–8, ≥99. Brain atrophy assessmentConﬂict of interestNone declared.FundingNone declared[1_TD$DIFF].
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McDonald diagnostic criteria for multiple sclerosis 2017.At least two clinical
attacks,
2 lesions with
objective clinical
evidenceNot requiredAt least two clinical
attacks,
1 lesion with
objective clinical
evidenceMultifocal CNS on MRI scan (Table 4)
or another clinical attack in a distinct
clinical locationOne clinical attack,
clinical evidence of
≥2 lesionsCNS damage developed over time on
MRI scan (Table 4) or
presence of CSF-speciﬁc oligoclonal
bands or
another clinical attack1 clinical attack, clin-
ical evidence of 1 le-
sion (clinically isolated
syndrome)Multifocal CNS damage developed
over time on MRI scan or
presence of CSF-speciﬁc oligoclonal
bandsPrimary progressive
multiple sclerosis1 year of disability progression (retro-
spectively or prospectively deter-
mined) and two of the following:
1. Multifocal lesions on MRI scan
2. Multifocal lesions on MRI scan of
the spinal cord (≥2 lesions)
3. Cerebrospinal ﬂuid analysis show-
ing presence of oligoclonal bands and/
or elevated immunoglobulin levelsr e f e r e n c e s
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